


Supplementary Material

Supplementary Figure 1. (A) IL-33 production in WT and mPGES-1 KO mice bmMFs by ELISA in pg/mL. (B) PGE₂ dose response in mPGES-1 KO and EP₂ KO bmMFs in comparison to WT cells. (C) IL-33 production by LPS stimulation in presence of PKA inhibitor KT5720. (D) Effect of PKA inhibitors H89 and KT5720 on PKA selective cAMP enhanced IL-33 production. (E) Effect of PKB/AKT signaling inhibitors - FPA124 and 10-DEBC in absence or (F) presence of PGE₂. (G) PGE₂ release by WT bmMFs upon LPS stimulation in presence of p38 MAPK and NF-κB inhibitors. Data are presented as mean (- ±SEM) of at least three independent experiments. Statistical significance was determined using unpaired t-test and one sample t-test (comparing fixed 100%), P value only <0.05 were considered as statistically significant [*p<0.05, **p<0.005].

Supplementary Figure 2. (A) Phospho-CREB and (B) phospho-AKT ELISAs on WT and (mPGES-1 & EP₂) KOs bmMFs upon LPS stimulation and further agonistic addition. Data are presented as mean (+SEM) of three independent experiments. Statistical significance was determined using unpaired t-test, P value only <0.05 were considered as statistically significant [*p<0.05]. (C) Levels of Phospho-ERK protein upon LPS stimulation and further addition of PGE₂ and cAMP. (D) Sequences for primers used in this study.

Supplementary Figure 1



Supplementary Figure 2

